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Background. Effect of cannabis use on memory function is a contentious issue, with effects being different in healthy
individuals and patients with psychosis.
Method. Employing a meta-analytic approach we investigated the effects of cannabis use on memory function in
patients with psychosis and healthy individuals, and the effect of diagnosis, memory dimension and moderating factors.
A total of 88 studies were identified through a systematic literature search, investigating healthy (n = 7697) and psychotic
(n = 3261) individuals. Standardized mean differences between the cannabis user and non-user groups on memory tasks
were estimated using random-effects models and the effect-size statistic Cohen’s d. Effects of potential moderating factors
were tested using mixed-effects models and subgroup analyses.
Results. We found that cannabis use was associated with significantly (p4 0.05) impaired global (d = 0.27) and prospect-
ive memory (d = 0.61), verbal immediate (d = 0.40) and delayed (d = 0.36) recall as well as visual recognition (d = 0.41)
in healthy individuals, but a better global memory (d =−0.11), visual immediate recall (d =−0.73) and recognition
(d =−0.42) in patients. Lower depression scores and younger age appeared to attenuate the effects of cannabis on mem-
ory. Cannabis-using patients had lower levels of depression and were younger compared with non-using patients, whilst
healthy cannabis-users had higher depression scores than age-matched non-users. Longer duration of abstinence from
cannabis reduced the effects on memory in healthy and patient users.
Conclusions. These results suggest that cannabis use is associated with a significant domain-specific impairment in
memory in healthy individuals but not in cannabis-using patients, suggesting that they may represent a less develop-
mentally impaired subgroup of psychotic patients.
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Introduction
Cannabis is one of the most frequently used illicit
drugs in the world (UN Office on Drugs and Crime,
2010). Young people are using it at an earlier age
(Smith & Flatley, 2011), to the extent that it is replacing
cigarette smoking as the most common substance used
by them (Moss et al. 2013). Based on evidence from ob-
servational studies, cannabis use has been linked to a
number of effects on cognition and behaviour
(Ranganathan & D’Souza, 2006; Solowij & Pesa,
2010), with memory being one of the most robustly
replicated cognitive functions which has been reported
to be impaired following chronic (non-acute) cannabis
use (Grant et al. 2003; Fletcher & Honey, 2006; Solowij
& Battisti, 2008; Solowij & Pesa, 2010; Schoeler &
Bhattacharyya, 2013). Meta-analyses of observational
studies comparing cannabis-using subjects with non-
using subjects have reported small (Grant et al. 2003)
to medium-sized effects (Schreiner & Dunn, 2012) of
cannabis on verbal memory performance, consistent
with evidence that regular cannabis use affects the
structure (Matochik et al. 2005; Yucel et al. 2008) and
function (Kanayama et al. 2004; Sneider et al. 2008) of
brain regions involved in memory processing. As dis-
cussed by Solowij & Battisti (2008), accumulating evi-
dence suggests that the magnitude and persistence of
cognitive impairment associated with cannabis use
depends on various parameters such as age of onset
(Pope et al. 2003; Gruber et al. 2012), dose (Bolla et al.
2002), frequency (Jager et al. 2006; Tait et al. 2011),
and duration of cannabis use (Meier et al. 2012) as
well as the period of abstinence from cannabis (Pope
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et al. 2001) at the time of testing, all of them interacting
with each other to predict the degree of impairment
(Wagner et al. 2010).
Δ-9-Tetrahydrocannabinol (THC), the main psycho-
active ingredient of cannabis, is thought to be respon-
sible for the adverse effects of cannabis on cognition.
Experimental studies involving acute challenge with
THC have reported that cannabis can impair short-
term (Morrison et al. 2009; Englund et al. 2013) and
long-term memory function (Curran et al. 2002;
D’Souza et al. 2004) and alter the neural substrates
underlying learning and memory (Bhattacharyya
et al. 2009, 2012) in healthy subjects, for which reason
THC administration has also been proposed as a strat-
egy to model and study schizophrenia pathophysi-
ology (Fletcher & Honey, 2006).
Among individuals suffering from a psychotic dis-
order, co-morbid substance use disorders including
cannabis use are higher than in the general population
(Koskinen et al. 2010). Cannabis use is also associated
with an increased risk of relapse (Linszen et al. 1997),
and of violence and criminal activity (Miles et al.
2003) in patients with psychosis. Although experimen-
tal acute challenge studies suggest that acute impair-
ments in memory induced by THC are greater in
those with a psychotic disorder (D’Souza et al. 2005)
than healthy controls, evidence from naturalistic stud-
ies in patients with psychosis have not been as straight-
forward. Epidemiological studies and meta-analyses
investigating the non-acute effects of cannabis use in
patient samples have either reported better perform-
ance in different domains of memory such as working
memory (Jockers-Scherubl et al. 2007; Løberg et al.
2008; Rabin et al. 2011) and verbal learning (Schnell
et al. 2009; Leeson et al. 2012) or no significant differ-
ence between cannabis-using and non-using patients
(Korver et al. 2010; Donoghue et al. 2012; Bahorik
et al. 2013).
The evidence summarized above suggests that the
same drug, which is known to be a risk factor for
psychosis and is associated with memory impairment
in healthy users, appears to have an association with
better memory performance in users with a psychotic
disorder. In light of these paradoxical trends in the
non-acute effects of cannabis use on memory in
healthy users v. those with psychosis, especially
when this is contrasted with experimental evidence
of the acute effects in these two groups (D’Souza
et al. 2005), the objective of the present study was to
systematically summarize the non-acute effects
(based on observational studies) of cannabis use on
memory function both in those with and without a
psychotic disorder. Elucidating this is important to ad-
vance current understanding of the association be-
tween cannabis use and psychosis and determinants
of this association, which in turn may help devise
intervention strategies. To our knowledge, no study
has as yet carried out a systematic quantitative synthe-
sis of the literature employing meta-analytic techni-
ques in both healthy and psychotic users regarding
the long-term effects of cannabis use on the different
subdomains within memory function, defined as a
multidimensional construct.
We employed a meta-analytic approach to statistical-
ly integrate the results from multiple individual stud-
ies. In the present analysis we have focused on
non-acute effects, thus including both residual and
chronic effects. We employed an inclusive definition
in order to have the power to detect the effect of canna-
bis use in both healthy and psychotic users. Hence, all
studies comparing cannabis users with non-users were
included, independent of the time of abstinence from
cannabis/results from urine tests. However, to address
the issue of residual effects, we examined the effect of
abstinence by carrying out moderation analysis
(described below). This allowed us to address the fol-
lowing questions:
(i) Does the non-acute effect of cannabis on memory
function differ significantly between healthy indi-
viduals and those with a psychotic disorder?
(ii) Is there a domain-specific effect of cannabis on
memory?
(iii) Are there particular demographic and individual
differences between healthy cannabis users and
cannabis-using patients with psychosis that may
be related to the differential effects of cannabis
use on memory in these two groups of cannabis
users?
(iv) Does the magnitude of the effect of cannabis use
on memory depend on certain cannabis use char-
acteristics such as frequency, duration, age of
onset of use and duration of abstinence at the
time of testing?
Method
Search strategy and selection criteria
Following recommended guidelines (Higgins & Green,
2008; Beller et al. 2013), a systematic search strategy
was used to identify all relevant studies. The
MEDLINE database was searched for English lan-
guage studies using a combination of search terms de-
scribing the outcome of interest (neuropsych*, cognit*,
memory, learning, recall) and cannabis use (marijuana/
marihuana, cannabis, THC, cannabinol, cannabidiol),
with the final search conducted on 27 June 2014.
Following further bibliography searches of previously
published reviews and meta-analyses (Gonzalez et al.
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2002; Grant et al. 2003; Potvin et al. 2008; Rabin et al.
2011; Donoghue & Doody, 2012; Schreiner & Dunn,
2012; Yücel et al. 2012), studies were selected if they
met the inclusion criteria (for a flowchart, see
Supplementary Fig. S1).
Recorded variables
Memory was considered as a multidimensional con-
struct (Kambeitz et al. 2012), including 11 distinct
memory dimensions, classified based on temporal
characteristics (i.e. from short-term memory to long-
term memory) or based on its content (i.e. verbal or
visual memory) (Pezdek & Evans, 1979) (see
Supplementary Fig. S1 and Supplementary Table S1).
As a common metric for the estimate of effect size,
Cohen’s d or the standardized mean difference
(SMD) between the means of cannabis users v.
non-users was estimated for each neuropsychological
test that measured an aspect of memory functioning.
This was followed by sensitivity analysis in a more
homogeneous group (Kambeitz et al. 2012) that
involved computing the effect-size estimate using the
same approach as above, but including only the data
from studies that employed the same memory test
(see Supplementary Appendix S1). Demographic and
clinical characteristics [pre-morbid intelligence quo-
tient (IQ), depression, anxiety and level of global func-
tioning] were compared using another set of SMDs
estimated from data for those measures reported as
means and standard deviations (see Supplementary
Table S2).
Following established guidelines, subgroup and meta-
regression analyses were carried out for duration, fre-
quency, age of onset and abstinence from cannabis use
as well as for cigarette and alcohol use and year of pub-
lication (for classification criteria, see Supplementary
Appendix S1).
Analysis
Analyses were conducted with the metaphor package
(Viechtbauer, 2010) in R, using random-effects models
(Lane et al. 2005) that assume that the SMDs vary from
study to study (Borenstein et al. 2011) (for details, see
Supplementary Appendix S1). Cohen’s d for memory
outcome was estimated according to established guide-
lines (Higgins & Green, 2008). In a second set of
random-effects models, SMDs for demographic and
clinical variables in cannabis users v. non-users were
estimated. Missing data, potential publication bias
and heterogeneity assessment were considered follow-
ing recommended procedures. To investigate sources
of heterogeneity, the influence of continuous moderator
variables, including the SMDs estimated for demo-
graphic and clinical variables, on Cohen’s d for memory
was tested using mixed-effect models (Viechtbauer,
2010).
Results
After excluding irrelevant studies or those that did not
satisfy our criteria, a final sample of n = 88 studies (num-
ber of domain-specific substudies k = 303), comprising
7697 healthy subjects and 3261 subjects with a psychotic
disorder was included (see Supplementary Fig. S1 and
Supplementary Table S3).
Random-effects models: effect of cannabis on
memory function in cannabis users with and without
a psychotic disorder
Cannabis use significantly impaired global memory
(d = 0.27, p < 0.0001; Fig. 1) in healthy cannabis users
relative to non-users. Conversely, in patients with
psychosis, cannabis use was associated with better
performance in these tasks, with a modest effect size
(d =−0.11, p = 0.05). Substantial overall heterogeneities
(I2 = 72%, see Supplementary Table S4) indicated that
moderators are likely to have influenced the effect of
cannabis use on memory (Song et al. 2001). Moderator
analysis indicated that the effect-size estimates were
significantly different (p < 0.0001) between the two diag-
nostic groups (patient v. healthy).
In the healthy sample, most of the memory dimen-
sions were significantly impaired by cannabis use,
with the most pronounced impairments being
observed for prospective memory. Within the patient
sample, cannabis users had either no impairments or
performed significantly better in several assessed
memory dimensions (working memory, visual imme-
diate recall, visual recognition, verbal recognition)
(Fig. 1). Moderator analysis indicated that the effect-
size estimates were significantly different (p < 0.001)
between the different memory dimensions within the
healthy sample, but not in the patients (p = 0.15).
Dimension-specific effects in healthy individuals were
not related to the size of sample examined for each di-
mension (Supplementary Table S5). Funnel plots
(Supplementary Fig. S2) and Egger’s test indicated
that publication bias was present within the healthy
sample (p < 0.005) but not the patient sample (p =
0.34) for global memory. The corrected model revealed
an effect-size estimate of Cohen’s d = 0.18 (p < 0.0001).
Supplementary Table S6 details the test results for pub-
lication bias for global memory and each memory di-
mension separately.
Sensitivity analysis to address the issue of hetero-
geneity in the measures employed resulted in an
even larger-sized, statistically significant effect of can-
nabis use on immediate recall (d = 0.52, p < 0.0001)
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and verbal learning (d = 0.52, p < 0.0001) in the healthy
sample by including only studies that employed the
Rey Auditory Verbal Learning Test (RAVLT) (see
Supplementary Table S7). Results with the RAVLT in
the patient sample were similar (immediate recall:
d =−0.10; verbal learning: d =−0.05) to the larger inclu-
sive sample.
Mixed-effects models: test of moderators
Clinical moderators of effects of cannabis action
Meta-regression (Supplementary Table S8) suggested a
significant moderating effect of SMDs (SMDs between
cannabis users and non-users) estimated for level of
functioning, pre-morbid IQ and level of depression,
implicating a more pronounced effect on global mem-
ory in those cannabis-using subjects with a lower level
of functioning and pre-morbid IQ, as well as higher
levels of depression relative to non-using controls.
We then examined the extent to which these factors
may have contributed to the different patterns of effect
of cannabis in healthy and patient groups, by compar-
ing the SMDs estimated for each moderator variable
per study between the two diagnostic groups (healthy
v. patients). As shown in Fig. 2, healthy cannabis users
showed higher levels of depression when compared
with non-users (SMD =−0.44, p < 0.0001), while in the
patient sample cannabis users had lower levels of de-
pression than non-users (SMD = 0.27, p < 0.0001).
Healthy cannabis users were characterized by lower
levels of functioning when compared with healthy
non-users (SMD = 0.83, p = 0.002), whilst no such effect
was present in the patient sample (SMD = 0.06, p =
0.43).
Effect of age
Meta-regression showed that age at the time of per-
formance of memory tasks significantly moderated
the adverse effects of cannabis use on memory (slope
coefficient of −0.20, p < 0.0001). This effect was such
that the younger the cannabis user compared with
the non-user at the time of cognitive testing, the smal-
ler was the magnitude of the adverse effect of cannabis
use on memory function. While cannabis users in the
healthy sample appeared to be matched in terms of
Fig. 1. Random-effects models for global memory and different memory dimensions in healthy subjects (■) and patients (▪).
Effect-size estimate Cohen’s d indicates differences in memory outcome between non-users and cannabis users,
with larger estimates reflecting worse performance in cannabis users. N is the number of subjects per memory
dimension, including cannabis users plus non-users. CI, Confidence interval.
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their mean age to the non-users (25.6 years v. 25.6
years, t = 0.30, p = 0.76), the cannabis-using patients
were on average 5 years younger than the non-using
patients (mean = 32.5 years v. 27.6 years, t = 9.08, p <
0.0001) (see Fig. 3).
Effect of cannabis use characteristics
Categorical moderator analysis revealed that those
cannabis users in the healthy and patient groups
abstaining from the substance for 10 days or more be-
fore performing memory tasks did better in memory
tests when compared with those who had abstained
for less than 10 days (Fig. 4). In the healthy sample,
significantly greater memory impairments were pre-
sent in heavy users when compared with moderate
or light users, while the frequency of cannabis use
was not a significant moderator in the patient sample.
There was a trend toward a dose–response relationship
(p = 0.06) between the duration of cannabis use and ef-
fect on memory, such that larger effect sizes were
reported in long-term healthy cannabis users com-
pared with short-term users. Age of onset of cannabis
use did not appear to moderate the adverse effects of
cannabis in both groups.
Effect of difference in co-morbid alcohol and nicotine use
Subgroup analysis suggested that differences in alco-
hol and nicotine use patterns did not significantly
(p < 0.05) moderate the effects of cannabis on memory
function (see Supplementary Fig. S3).
Effect of year of publication
In the healthy sample, there was a significant effect of
date of publication on the effect of cannabis on
memory, i.e. studies that were published before 2000
reported a significant but small effect size of d = 0.12,
whereas studies published after 2000 reported a signifi-
cant moderate effect size of d = 0.31, which were signifi-
cantly different in comparison (p = 0.01; see Fig. 5). This
comparison could not be carried out in the patient
sample, considering that all of the studies in patients
were published after 2000 (see Supplementary
Table S3).
Discussion
Results presented here suggest that cannabis use has a
robust but modest adverse effect on global memory
function as well as its multiple component dimensions
in healthy cannabis users, with the precise magnitude
of the effect depending on the specific dimension of
memory tested. This replicates the results of previous
reviews (Solowij & Battisti, 2008) and meta-analyses
that reported small impairments in memory in healthy
cannabis users, with effect sizes ranging from d = 0.16
to d = 0.32 (Grant et al. 2003; Schreiner & Dunn, 2012).
Furthermore, our results implicate selective effects of
cannabis on aspects of memory in healthy users, with
the largest effect sizes reported for prospective (d =
0.61) and retrospective memory with both verbal (e.g.
verbal learning, immediate and delayed recall) and vis-
ual content (e.g. visual recognition). In practical terms,
these results suggest that the effects of cannabis use are
more likely to be expressed in impairments in
day-to-day activities that require the ability to remem-
ber to carry out the intended task at some point of time
in the future (e.g. meeting a friend or taking medica-
tion) or problems in recalling events from the past
(e.g. recalling past conversations). The effects on rather
Fig. 2. Differences in standardized mean difference (SMD) for clinical factors between healthy subjects (■) and patients (▪).
SMDs in clinical parameters [depression scores, pre-morbid intelligence quotient (IQ) and functioning scores]
are shown between non-users and cannabis users, with larger SMDs reflecting lower scores (lower depression
levels, lower pre-morbid IQ, lower functioning) in cannabis users. The p value is the estimated significance level
for the categorical moderator (healthy v. patients) in mixed-effects models for SMD in depression scores,
pre-morbid IQ and functioning scores between non-users and cannabis users. CI, Confidence interval.
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Fig. 4. Categorical moderator analysis based on cannabis use patterns in healthy subjects (■) and patients (▪). Effect-size
estimate Cohen’s d indicates differences in memory outcome between non-users and cannabis users, with larger
estimates reflecting worse performance in cannabis users. The p value is the estimated significance level for
each categorical moderator (i.e. frequency of use, duration of use, onset of use, abstinence from cannabis) in
moderator analysis. ‘Light user’ indicates less than four times/month or less than 10 joints/month; ‘regular user’
indicates between four and 20 times/month or between 10 and 25 joints/month; ‘heavy user’ indicates diagnosis
of cannabis dependence or more than 20 times/month or more than 30 joints/month; ‘short term user’ indicates
cannabis use less than 2500 days of use; ‘long term user’ indicates more than 5000 days of use; ‘early onset
user’ indicates cannabis use before the age of 17 years; ‘late onset user’ indicates cannabis use after the age of
17 years; ‘short abstinence’ indicates less than 10 days of abstinence; ‘long abstinence’ indicates more than 10
days of abstinence; CI, confidence interval; N/A, not applicable.
Fig. 3. Mean differences in age between groups. There were significant differences in mean age between cannabis users and
non-users in patients (p < 0.0001) but not the healthy sample (p = 0.76).
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longer-term memory functions may also reflect the
high density of CB1 receptors, the main target of can-
nabinoids, in brain structures critically involved in
longer-term memory processes such as the hippocam-
pus, basal ganglia and cerebellum (Herkenham et al.
1990; Eichenbaum, 1993; Packard & Knowlton, 2002),
with cannabinoids preventing hippocampal long-term
potentiation, a potential substrate for memory (for a re-
view, see Iversen, 2003) through a downstream effect
on a number of neuromodulator/ neurotransmitter sys-
tems (Pertwee, 2008). Strikingly, the results indicate
better overall memory performance in cannabis-using
patients when compared with non-users (d =−0.11),
particularly for the domains of visual immediate recall
(d =−0.73), verbal recognition (d =−0.34) and visual
recognition (d =−0.41), which is in line with earlier
meta-analytical findings of either a lack of adverse ef-
fect of cannabis on cognitive abilities in patients with
a psychotic disorder (Løberg & Hugdahl, 2009; Yücel
et al. 2012) or association with better attention and psy-
chomotor speed (Donoghue & Doody, 2012), reason-
ing, problem-solving and visual memory (Potvin
et al. 2008) and neurological soft signs (Ruiz-Veguilla
et al. 2012). A recent meta-analysis also reported that
psychotic patients with unspecified co-morbid substance
use disorder performed significantly better in tests
measuring verbal learning and memory (d =−0.26)
than those without (Donoghue & Doody, 2012).
Better verbal memory function related to substance
use has also been reported in a subsequent study com-
prising a sample of first-episode psychosis for verbal
memory function (Lutgens et al. 2014), while no effect
of polydrug use was present on working memory
in schizophrenia patients (Wojtalik & Barch, 2014).
Similarly, no adverse effects of cocaine on verbal learn-
ing and memory were present in patient samples
(Donoghue & Doody, 2012). In summary, cannabis
appears to have differential effects on memory in
users with and without a psychotic disorder, a
phenomenon that has also been referred to as the para-
dox effect of the dually diagnosed (Penk et al. 2000;
Moreno-Granados et al. 2014).
Meta-regression indicated that several factors such
as lower levels of depression, higher levels of function-
ing and a younger age at the time of cognitive assess-
ment may have attenuated the adverse effects of
cannabis on memory, whilst other factors such as
years of education, level of anxiety, co-morbid nicotine
and alcohol use did not appear to moderate the effects
of cannabis. First, on comparing the healthy and patient
groups, cannabis-using patients appeared to be less
depressed than the non-users, while an opposite pat-
tern was evident in the healthy sample. This may sug-
gest that co-morbid depressive symptoms may partly
account for the apparent opposite effects of cannabis
use on memory function in healthy users v. those
with a psychotic disorder. In fact, depressive symp-
toms have been associated with impairments in cogni-
tive function in healthy subjects, including episodic
and semantic memory, as well as executive function
(McDermott & Ebmeier, 2009), and have also been
linked to impairments in recall and recognition mem-
ory in schizophrenia patients (Burt et al. 1995).
Second, age differences between cannabis users and
non-users may have significantly moderated the effect
of cannabis use on memory. Adverse effects of canna-
bis on memory seemed to increase with increasing age
differences between cannabis users and non-user (i.e.
the older the cannabis user in comparison with the
non-user, the larger the impairing effect of cannabis
on memory), consistent with a previous meta-analysis
reporting an association between older age and a
stronger detrimental effect of cannabis use on global
cognition, as well as on working memory and process-
ing speed in patients with a psychotic disorder (Potvin
et al. 2008). This may in fact be an effect of age-related
worsening of memory performance (Vakil & Blachstein,
1997; Benedict et al. 1998), unrelated to the effect of
Fig. 5. Categorical moderator analysis: year of publication. Standardized mean differences (SMDs) are shown in memory
outcome between non-users and cannabis users in the healthy sample, with larger SMDs reflecting worse performance in
cannabis users. The p value is the estimated significance level for the categorical moderator year of publication (before 2000 v.
after 2000). ‘Before 2000’ indicates studies published before the year 2000; ‘after 2000’ indicates studies published after the
year 2000. CI, Confidence interval.
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cannabis exposure or the duration of exposure to
cannabis. In the studies included in the present meta-
analysis, healthy cannabis users and non-users did
not differ in their average age, implicating that age
was not a confounding factor in this group. However,
in the studies that investigated patients with psychosis,
cannabis-using patients were on average 5 years
younger than the non-users (see Fig. 3). Performance
in verbal memory tests are sensitive to changes in
age of testing within the age ranges of participants
reported in these studies (Hulicka, 1966), with younger
age being associated with better performance in the
Hopkins Verbal Learning Test (Benedict et al. 1998)
as well as in learning and recall measures from the
RAVLT (Vakil & Blachstein, 1997). This may partly ex-
plain the better memory performance in cannabis-using
patients relative to non-users.
A further explanation for the paradoxical findings in
patients lies in the fact that many patients with schizo-
phrenia are thought to have a neurodevelopmental dis-
order (Murray & Lewis, 1987) while drug abuse may
provide an alternative pathway to developing psych-
osis (Murray et al. 2013). Such a view would suggest
that cannabis-using patients with psychosis may re-
present a subgroup with less neurodevelopmental
pathology (Yücel et al. 2012; Ferraro et al. 2013) and
less neurocognitive impairment than non-using
patients in the first place. Perhaps, another explanation
that does not pitch the neurodevelopmental pathway
and drug abuse as alternative pathways to psychosis
may be that cannabis-using patients with psychosis
have better neurocognitive function to begin with.
This idea is further supported by reports of absence
of impaired cognition in association with use of a num-
ber of psychoactive substances (alcohol, cannabis, hal-
lucinogens, cocaine, stimulants) in those with
psychosis (Pencer & Addington, 2003; Potvin et al.
2008) and evidence that substance-using schizophrenia
patients were characterized by better social functioning
and fewer negative symptoms when compared with
non-users (Salyers & Mueser, 2001; Carey et al. 2003).
Duration of abstinence from cannabis had a signifi-
cant effect on memory function in both groups, such
that the longer the duration of abstinence from canna-
bis, the smaller was the size of impairment observed,
suggesting perhaps that worse memory performance
associated with cannabis use may be largely but not
completely reversible. These results are consistent
with studies in healthy users reporting smaller effects
of cannabis on memory in former users when com-
pared with those who had never used (Fried et al.
2005) and reversible effects of cannabis on short-term
memory function following abstinence in humans
(Pope et al. 2001; Tait et al. 2011) and animals
(Nakamura et al. 1991). Frequency of cannabis use
also appeared to moderate the effects on memory in
healthy individuals but not in patients consistent
with evidence that the effects of cannabis are likely
to depend on dose (Curran et al. 2002) and frequency
of use (Fried et al. 2005). The evidence is less clear in
this regard in patients with psychosis, with abstinence
being associated with better performance in some
(Rabin et al. 2012) but not all studies (Bugra et al.
2013). Similarly, an association between cognitive per-
formance and duration and frequency of cannabis use
was found in some studies including patients with
psychosis (Wobrock et al. 2013), whilst others failed
to show a correlation between duration of cannabis ex-
posure and age at first cannabis use (Cunha et al. 2013).
An interesting trend in our analysis was the doub-
ling of the effect on memory in healthy cannabis
users reported in studies published after 2000 relative
to those in the previous period (see Fig. 5). More specu-
latively, this may be related to the changing potency of
cannabis that is used recreationally (Bowman & Pihl,
1973; Soueif, 1976). In contrast to old-fashioned herbal
cannabis and resin consumed in the 1970s and 1980s,
for example comprising about 3–4% THC (Poulsen &
Sutherland, 2000), THC content in currently available
herbal cannabis has increased to about 8%, and
‘skunk’ or sinsemilla is increasingly dominating the
market in the UK and other European countries, a
more potent variant containing about 16% THC
(Hardwick & King, 2008). However, in this context
we cannot rule out the possibility that some of the
between-study variation arose owing to changes in
the quality of research conducted, i.e. that greater
methodological rigor was introduced by studies pub-
lished after 2000.
Certain limitations are to be considered when inter-
preting the results of the present meta-analysis. First, a
causal relationship between cannabis use and memory
impairments cannot be inferred given the cross-
sectional nature of the studies. Methodological hetero-
geneity of studies included is another important caveat
inherent to the meta-analytic approach. In particular
for the present meta-analysis, an obvious limitation is
related to the use of different cognitive tests adminis-
tered to measure the same memory dimension.
Combining the results of different cognitive tests
meta-analytically is an approach that has been
employed before (Kambeitz et al. 2012) and sensitivity
analysis indicates that this is unlikely to be an issue
(see Supplementary Table S7). Conclusions regarding
the impact of depression and differences in functioning
between the patients v. healthy samples and cannabis
user v. non-user comparison groups are of limited gen-
eralizability, given the diversity of measures adminis-
tered to measure level of functioning, depression and
pre-morbid IQ (see Supplementary Table S2).
184 T. Schoeler et al.
https://doi.org/10.1017/S0033291715001646
Downloaded from https://www.cambridge.org/core. UB der LMU München, on 03 Dec 2018 at 13:35:23, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Furthermore, they have been administered by raters
with different backgrounds (e.g. clinically trained v.
non-trained researchers v. self-ratings by subjects) in
different contexts (e.g. psychiatric services v. research
facilities). Another important limitation relates to het-
erogeneity in the criteria used to define the user v. non-
user subgroups in the studies (see Supplementary
Table S9). This was less of a problem in studies involv-
ing healthy individuals, with only one study defining
non-users as those who did not use cannabis in the pre-
vious year (Wadsworth et al. 2006) and one defining
non-users as those who were not diagnosed with can-
nabis use disorder at the assessment (Smith et al. 2014),
whilst the remaining studies defined non-users as
those who never used cannabis in their life or never
used the substance regularly. Caution is also war-
ranted in interpreting the present data regarding the
moderating effects of cannabis use patterns such as ab-
stinence, frequency, duration and age of onset of use,
as they were mainly based on self-reports and hence
represent only crude approximations of actual expo-
sures. Effects of these moderators were investigated in-
dependently, rather than within multifactorial
prediction models, which was not possible in this
meta-analysis as only a few studies reported data on
all parameters of cannabis use. However, this limits
the interpretation of these results, given that these
moderators interact with each other to influence memory
(Wagner et al. 2010) and the results may be susceptible
to bias considering that only a subset of studies was
available for moderator analysis (see Supplementary
Table S10). It is also worth noting that various factors
may underlie motivation to use cannabis among
patients with psychosis, including using it as a form
of self-medication. Consistent with this idea, it may
be possible that some patients may have used cannabis
to treat their pre-existing cognitive deficits. However,
this aspect was not addressed in the present paper as
the focus of this meta-analysis was not to investigate
the reasons as to why patients with psychosis use can-
nabis, but to estimate the magnitude of the effects of
cannabis on memory, irrespective of the reasons for
its use. Generalizability of the results may also be lim-
ited to Europe, North America and Australia, as only a
few studies came from Asia or Africa.
Conclusions
These results confirm that regular cannabis use impairs
memory function across a range of different memory
domains, at least in healthy individuals. A similar ad-
verse effect was not observed in patients with psych-
osis, which may reflect the possibility that cannabis
users among patients with psychosis comprise a less
depressed, less developmentally impaired, and
younger subgroup in comparison with non-using
patients. Duration of abstinence from cannabis
appeared to reduce the effects on memory in both
healthy individuals and patients with a psychotic dis-
order, underlining the importance of harm-reduction
strategies. Our findings highlight a need for future
studies employing longitudinal design in adequately
matched participant groups on potential confounding
factors, to definitively establish the effects of regular
use of the world’s most widely used illicit drug on
memory function.
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